Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 27 November, 2024
Author: Getaka|Social: Getaka Financial Services X (Earlier Twitter) Profile Getaka Financial Services LinkedIn Logo
Stock Ticker - BSE: 532998 | NSE: LOTUSEYE

Lotus Eye Hospital & Institute Ltd: Intrinsic Value and Fundamental Analysis

Share Price and Basic Stock Data

Last Updated: November 26, 2024, 9:43 pm

Market Cap 144 Cr.
Current Price 69.6
High / Low97.4/44.1
Stock P/E101
Book Value 28.9
Dividend Yield0.00 %
ROCE7.07 %
ROE4.97 %
Face Value 10.0
PEG Ratio14.95

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Lotus Eye Hospital & Institute Ltd

Competitors of Lotus Eye Hospital & Institute Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Lotus Eye Hospital & Institute Ltd 144 Cr. 69.697.4/44.1101 28.90.00 %7.07 %4.97 % 10.0
Industry Average144.00 Cr69.60101.0028.900.00%7.07%4.97%10.00

All Competitor Stocks of Lotus Eye Hospital & Institute Ltd

Quarterly Result

MonthJun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
Sales5.9210.8111.6110.5711.8711.8612.1411.1712.5712.7312.0310.8812.89
Expenses5.758.729.269.339.5510.1010.039.7810.1810.9210.4510.1211.23
Operating Profit0.172.092.351.242.321.762.111.392.391.811.580.761.66
OPM %2.87%19.33%20.24%11.73%19.55%14.84%17.38%12.44%19.01%14.22%13.13%6.99%12.88%
Other Income0.170.210.220.280.240.230.320.360.290.280.340.400.31
Interest0.020.040.040.030.030.030.020.020.020.010.040.030.06
Depreciation0.530.600.630.750.680.750.770.780.730.890.981.121.06
Profit before tax-0.211.661.900.741.851.211.640.951.931.190.900.010.85
Tax %-4.76%24.70%26.84%27.03%26.49%24.79%29.88%31.58%27.98%28.57%26.67%-200.00%28.24%
Net Profit-0.201.251.390.541.370.901.160.651.380.850.660.020.62
EPS in Rs-0.100.600.670.260.660.430.560.310.660.410.320.010.30

Last Updated: October 17, 2024, 2:13 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: October 17, 2024, 2:13 pm

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024TTM
Sales29.1128.6929.9031.1333.9638.0238.4340.5532.3538.9047.0348.2048.53
Expenses25.5125.4027.7227.1430.6333.6835.2136.5728.7332.9839.3541.5742.72
Operating Profit3.603.292.183.993.334.343.223.983.625.927.686.635.81
OPM %12.37%11.47%7.29%12.82%9.81%11.42%8.38%9.82%11.19%15.22%16.33%13.76%11.97%
Other Income0.640.390.460.580.680.910.680.210.840.881.151.311.33
Interest0.050.040.100.160.150.180.210.240.140.210.200.200.14
Depreciation3.733.544.764.443.443.373.062.502.332.502.983.734.05
Profit before tax0.460.10-2.22-0.030.421.700.631.451.994.095.654.012.95
Tax %8.70%60.00%-10.81%-400.00%-7.14%-2.35%-12.70%26.90%21.11%27.14%27.79%27.43%
Net Profit0.420.04-1.980.100.441.750.711.061.572.984.082.912.15
EPS in Rs0.200.02-0.950.050.210.840.340.510.751.431.961.401.04
Dividend Payout %0.00%0.00%0.00%0.00%236.36%59.43%0.00%0.00%66.24%34.90%25.49%0.00%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2013-20142014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-2024
YoY Net Profit Growth (%)-90.48%-5050.00%105.05%340.00%297.73%-59.43%49.30%48.11%89.81%36.91%-28.68%
Change in YoY Net Profit Growth (%)0.00%-4959.52%5155.05%234.95%-42.27%-357.16%108.72%-1.18%41.70%-52.90%-65.59%

Lotus Eye Hospital & Institute Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:5%
5 Years:5%
3 Years:14%
TTM:0%
Compounded Profit Growth
10 Years:54%
5 Years:33%
3 Years:24%
TTM:-65%
Stock Price CAGR
10 Years:21%
5 Years:25%
3 Years:15%
1 Year:-18%
Return on Equity
10 Years:3%
5 Years:5%
3 Years:6%
Last Year:5%

Last Updated: Unknown

Balance Sheet

Last Updated: November 14, 2024, 8:37 pm

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital20.8020.8020.8020.8020.8020.8020.8020.8020.8020.8020.8020.8020.80
Reserves30.5330.5728.5928.6929.2629.8429.3230.4631.9033.8136.7838.6139.31
Borrowings0.260.180.830.660.480.290.220.320.401.240.671.110.00
Other Liabilities5.317.016.204.684.407.286.186.536.125.754.936.119.96
Total Liabilities56.9058.5656.4254.8354.9458.2156.5258.1159.2261.6063.1866.6370.07
Fixed Assets45.3146.9447.0443.5741.3242.5244.1442.6740.5444.0744.1848.6552.84
CWIP0.180.360.270.420.650.290.290.000.000.000.000.080.00
Investments0.000.000.000.000.000.000.000.000.000.000.000.000.00
Other Assets11.4111.269.1110.8412.9715.4012.0915.4418.6817.5319.0017.9017.23
Total Assets56.9058.5656.4254.8354.9458.2156.5258.1159.2261.6063.1866.6370.07

Reserves and Borrowings Chart

Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity +3.714.412.373.382.975.784.204.972.734.414.395.68
Cash from Investing Activity +-1.20-5.05-4.65-0.85-1.06-3.86-4.01-0.680.49-3.94-2.19-4.63
Cash from Financing Activity +-0.16-0.771.87-0.58-0.25-1.51-1.410.13-0.32-1.58-1.71-3.40
Net Cash Flow2.35-1.41-0.401.961.660.41-1.224.422.90-1.100.49-2.35

Free Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Free Cash Flow3.343.111.353.332.854.053.003.663.224.687.015.52

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days3.894.964.275.987.3110.947.225.948.355.829.089.54
Inventory Days135.42166.70121.54113.2560.2279.23128.20124.42138.82150.03153.60170.30
Days Payable160.79130.52125.08105.5187.32129.95167.37170.41220.72231.21173.42183.56
Cash Conversion Cycle-21.4841.140.7313.72-19.79-39.78-31.95-40.05-73.54-75.37-10.74-3.72
Working Capital Days0.25-13.10-19.90-8.56-8.92-26.02-14.53-21.33-20.99-10.9812.348.86
ROCE %0.99%0.27%-4.23%0.24%1.19%3.63%1.66%4.67%3.92%7.91%10.25%7.07%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthDec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
Promoters57.74%57.74%57.74%57.88%58.14%58.17%58.44%57.58%56.58%41.40%40.24%40.03%
Public42.26%42.26%42.26%42.12%41.86%41.83%41.56%42.43%43.42%58.60%59.76%59.97%
No. of Shareholders6,2266,8307,0317,4167,4167,3457,4257,6608,31412,50211,75912,514

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue10.0010.0010.0010.0010.00
Basic EPS (Rs.)1.401.961.440.750.51
Diluted EPS (Rs.)1.401.961.440.750.51
Cash EPS (Rs.)3.193.392.641.871.71
Book Value[Excl.RevalReserv]/Share (Rs.)28.5727.6926.2625.3424.65
Book Value[Incl.RevalReserv]/Share (Rs.)28.5727.6926.2625.3424.65
Dividend / Share (Rs.)0.500.500.500.500.00
Revenue From Operations / Share (Rs.)23.1822.6218.7115.5619.50
PBDIT / Share (Rs.)3.774.203.242.072.27
PBIT / Share (Rs.)1.972.772.030.951.07
PBT / Share (Rs.)1.932.721.970.950.69
Net Profit / Share (Rs.)1.401.961.440.750.51
PBDIT Margin (%)16.2418.5617.3013.3011.62
PBIT Margin (%)8.5112.2210.876.105.47
PBT Margin (%)8.3212.0110.526.153.58
Net Profit Margin (%)6.048.667.674.842.62
Return on Networth / Equity (%)4.907.085.462.972.07
Return on Capital Employeed (%)6.799.917.573.694.23
Return On Assets (%)4.376.454.842.641.82
Asset Turnover Ratio (%)0.740.750.640.550.70
Current Ratio (X)2.252.832.242.341.75
Quick Ratio (X)1.742.301.842.031.41
Inventory Turnover Ratio (X)2.813.283.192.612.66
Dividend Payout Ratio (NP) (%)35.670.000.000.000.00
Dividend Payout Ratio (CP) (%)15.650.000.000.000.00
Earning Retention Ratio (%)64.330.000.000.000.00
Cash Earning Retention Ratio (%)84.350.000.000.000.00
Interest Coverage Ratio (X)80.4289.4752.5666.3566.88
Interest Coverage Ratio (Post Tax) (X)30.8642.8024.3823.9125.92
Enterprise Value (Cr.)110.46112.37102.1077.2241.44
EV / Net Operating Revenue (X)2.292.392.622.391.02
EV / EBITDA (X)14.1012.8715.1717.938.79
MarketCap / Net Operating Revenue (X)2.442.572.852.691.19
Retention Ratios (%)64.320.000.000.000.00
Price / BV (X)1.982.102.031.650.94
Price / Net Operating Revenue (X)2.442.572.852.691.19
EarningsYield0.020.030.020.010.02

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Lotus Eye Hospital & Institute Ltd as of November 27, 2024 is: 147.97

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of November 27, 2024, Lotus Eye Hospital & Institute Ltd is Undervalued by 112.60% compared to the current share price 69.60

Intrinsic Value of Lotus Eye Hospital & Institute Ltd as of November 27, 2024 is: 157.97

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of November 27, 2024, Lotus Eye Hospital & Institute Ltd is Undervalued by 126.97% compared to the current share price 69.60

Last 5 Year EPS CAGR: 6.76%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a low average Working Capital Days of -10.24, which is a positive sign.
  2. The stock has a low average Cash Conversion Cycle of -21.74, which is a positive sign.
  3. The company has higher reserves (32.13 cr) compared to borrowings (0.51 cr), indicating strong financial stability.
  4. The company has shown consistent growth in sales (37.29 cr) and profit (1.63 cr) over the years.
  1. The stock has a low average ROCE of 3.13%, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Lotus Eye Hospital & Institute Ltd:
    1. Net Profit Margin: 6.04%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 6.79% (Industry Average ROCE: 7.07%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 4.9% (Industry Average ROE: 4.97%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 30.86
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 1.74
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 101 (Industry average Stock P/E: 101)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Lotus Eye Hospital and Institute Ltd. is a Public Limited Listed company incorporated on 14/03/1997 and has its registered office in the State of Tamil Nadu, India. Company’s Corporate Identification Number(CIN) is L85110TZ1997PLC007783 and registration number is 007783. Currently company belongs to the Industry of Hospitals & Medical Services. Company’s Total Operating Revenue is Rs. 38.91 Cr. and Equity Capital is Rs. 20.80 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
Hospitals & Medical ServicesS.F No.770/12, Avinashi Road, Coimbatore Tamil Nadu 641014companysecretary@lotuseye.org
http://www.lotuseye.org
Management
NamePosition Held
Dr. Kavetha SundaramoorthyChairman
Ms. Sangeetha SundaramoorthyManaging Director
Dr. K S RamalingamWholeTime Director & CEO
Dr. S NatesanDirector
CA. Perumalsamy MahendranDirector
CA. M AlagiriswamyDirector
Mr. Karthik VeeramaniDirector
Mr. D R KaarthikeyanDirector
Dr. Yogesh ShahDirector

FAQ

What is the latest intrinsic value of Lotus Eye Hospital & Institute Ltd?

The latest intrinsic value of Lotus Eye Hospital & Institute Ltd as on 27 November 2024 is ₹147.97, which is 112.60% higher than the current market price of ₹69.60. The stock has a market capitalization of 144 Cr. and recorded a high/low of ₹97.4/44.1 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹39.31 Cr and total liabilities of ₹70.07 Cr.

What is the Market Cap of Lotus Eye Hospital & Institute Ltd?

The Market Cap of Lotus Eye Hospital & Institute Ltd is 144 Cr..

What is the current Stock Price of Lotus Eye Hospital & Institute Ltd as on 27 November 2024?

The current stock price of Lotus Eye Hospital & Institute Ltd as on 27 November 2024 is ₹69.6.

What is the High / Low of Lotus Eye Hospital & Institute Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Lotus Eye Hospital & Institute Ltd stocks is 97.4/44.1.

What is the Stock P/E of Lotus Eye Hospital & Institute Ltd?

The Stock P/E of Lotus Eye Hospital & Institute Ltd is 101.

What is the Book Value of Lotus Eye Hospital & Institute Ltd?

The Book Value of Lotus Eye Hospital & Institute Ltd is 28.9.

What is the Dividend Yield of Lotus Eye Hospital & Institute Ltd?

The Dividend Yield of Lotus Eye Hospital & Institute Ltd is 0.00 %.

What is the ROCE of Lotus Eye Hospital & Institute Ltd?

The ROCE of Lotus Eye Hospital & Institute Ltd is 7.07 %.

What is the ROE of Lotus Eye Hospital & Institute Ltd?

The ROE of Lotus Eye Hospital & Institute Ltd is 4.97 %.

What is the Face Value of Lotus Eye Hospital & Institute Ltd?

The Face Value of Lotus Eye Hospital & Institute Ltd is 10.0.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Lotus Eye Hospital & Institute Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE